Balaglitazone, also known as DRF-2593; NNC-61-0645; NNC-61-2344; NN-2344; NNC-610645; NNC-612344, is an agonist of peroxisome proliferator-activated receptor (PPAR)γ. Balaglitazone plays an important role in the regulation of insulin, triglycerides and lipid metabolism. It is an attractive target for the therapy of Type II Diabetes. Balaglitazone is a partial agonist of PPARγ. It has showed potent effects on lowering blood glucose in various animal models. Balaglitazone passed phase III clinical trial for the treatment of type 2 diabetes. However, Dr. Reddy's Laboratories decided to terminate further clinical development of balaglitazone. Balaglitazone exists as two enantiomers: BALAGLITAZONE, (S)- and BALAGLITAZONE, (R)-. A capillary electrophoresis method for separation of a racemic mixture of glitazone compounds has being used. The method separated the R and S enantiomers of balaglitazone, and showed that the samples contained an equal (50:50) quantity of the enantiomers as a mixture. The Rs for the separations were 3.5 for balaglitazone enantiomers.

CJ-033466 is experimental drug, which acts as selective 5-HT4 serotonin receptor partial agonist. It was originally synthesized at Pfizer Laboratories, and it was specifically exemplified in Pfizer patent applications (WO2003035649 and WO2004026869). In animal tests, it stimulated gastrointestinal motility with 30 times the potency of cisapride. CJ-033,466 does not affect D2 and other 5-HT receptors, and it is a potential therapy for gastroparesis patients.

BMS-442606 is an S-enantiomer of 6-hydroxybuspirone and is a 5-HT1A partial agonist. BMS-442606 has advantage of being cleared more slowly from blood compared to the R-enantiomer, but R form showed higher affinity and selectivity for the 5HT1A receptor compared to the S-isomer. Because both isomers together with racemic form were well tolerated and was not found any advantage of one of the enantiomers of over the racemic form. Finally, racemic form was chosen for further clinical development.

L-838,417 is a subtype-selective GABAA modulator, acting as a partial agonist at alpha2, alpha3 and alpha5 subtypes and an antagonist at the alpha1 subtype. L-838,417 displays anxiolytic effects in vivo and is used as a tool compound to study roles of GABAA subunits.

Gambogic acid (GA), a naturally occurring xanthone-based moiety, reported from Garcinia hanburyi tree, is known to perform numerous intracellular and extracellular actions, including programmed cell death, autophagy, cell cycle arrest, antiangiogenesis, antimetastatic, and anti-inflammatory activities. In addition, GA-based synergistic approaches have been proven to enhance the healing strength of existing chemotherapeutic agents along with lesser side effects. Among cellular targets of gambogic acid topoisomerase, multidrug-resistant protein ATP-binding cassette transporter B1 (ABCB1) and Transferrin receptor.